Infliximab for the treatment of refractory adamantiades-behçet disease with articular, intestinal, cerebral and ocular involvement

Dermatology

Volumn 220, Issue 3, 2010, Pages 282-286

  Donghi, Davide ^a   Mainetti, Carlo ^a  

^a REGIONAL HOSPITAL OF LUGANO   (Switzerland)

Author keywords

Adamantiades Beh et disease; Cerebral vasculitis; HLA B51; Ileocaecal bleeding; Infliximab; Monoarthritis; Oral and genital ulcerations; Retinal vasculitis

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; AZATHIOPRINE; C REACTIVE PROTEIN; COLCHICINE; CORTICOSTEROID; HLA B51 ANTIGEN; INFLIXIMAB; METHYLPREDNISOLONE; PREDNISONE;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADAMANTIADE BEHCET DISEASE; ADAMANTIADES BEHCET DISEASE; ADOLESCENT; ALBANIA; ANEMIA; ANTIGEN DETECTION; APHTHOUS ULCER; BLOODY DIARRHEA; BRAIN VASCULITIS; CASE REPORT; CENTRAL SCOTOMA; CLINICAL FEATURE; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMPIRICISM; ENDOSCOPIC BIOPSY; HISTOPATHOLOGY; HUMAN; ILEITIS; ILEOCECAL VALVE; IMMUNOSUPPRESSIVE TREATMENT; INTESTINAL BLEEDING; INTESTINE ULCER; IRON DEFICIENCY ANEMIA; JOINT SWELLING; KNEE PAIN; LETTER; MALE; MONARTHRITIS; MOUTH ULCER; NECROSIS; NEUTROPHIL CHEMOTAXIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOSCOPY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; RETINA ANGIOGRAPHY; RETINA VASCULITIS; SCROTUM DISORDER; SKIN BIOPSY; SYNOVECTOMY; SYNOVIORTHESIS; VASCULITIS; VISUAL IMPAIRMENT;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ARTHRITIS; ASPIRIN; AZATHIOPRINE; BEHCET SYNDROME; CHRONIC DISEASE; COLCHICINE; HLA-B ANTIGENS; HUMANS; ILEITIS; MAGNETIC RESONANCE IMAGING; MALE; PREDNISONE; RETINAL VASCULITIS; SCROTUM; VASCULITIS, CENTRAL NERVOUS SYSTEM;

EID: 77951878847     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000277928     Document Type: Letter

References (45)

1. International Study Group for Behçet's Disease: Criteria for diagnosis of Behçet's disease. Lancet 1990; 335: 1078-1080.
2. Zouboulis CC: Adamantiades-Behçet disease; in Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ (eds): Fitzpatrick's Dermatology in General Medicine, ed 7. New York, McGraw Hill, 2008, pp 1620-1626.
3. Akman-Demir G, Serdaroglu P, Tasci B: Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. The Neuro-Behçet Study Group. Brain 1999; 122: 2171-2182.
4. Kalayciyan A, Zouboulis CC: An update on Behçet's disease. J Eur Acad Dermatol Venereol 2007; 21: 1-10.
5. Evereklioglu C, Er H, Türkoz Y, Cekmen M: Serum levels of TNF-α, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet disease. Mediators Inflamm 2002; 11: 87-93.
6. Sfikakis PP: Behçet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 2002; 61(suppl):ii51-ii53.
7. Sfikakis PP, Markomichelakis N, Alpsoy E, Assaad-Khalil S, Bodaghi B, Gul A, Ohno S, Pipitone N, Schirmer M, Stanford M, Wechsler B, Zouboulis C, Kaklamanis P, Yazici H: Anti-TNF therapy in the management of Behçet's disease - review and basis for recommendations. Rheumatology (Oxford) 2007; 46: 736-741.
8. Baki K, Villiger PM, Jenni D, Meyer T, Beer JH: Behçet's disease with life-threatening haemoptoe and pulmonary aneurysms: complete remission after infliximab treatment. Ann Rheum Dis 2006; 65: 1531-1532.
9. Muñoz-Fernández S, Hidalgo V, Fernández-Melón J, Schlincker A, Martín-Mola E: Effect of infliximab on threatening panuveitis in Behçet's disease. Lancet 2001; 358: 1644.
10. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN: Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet 2001; 358: 295-296.
11. Takamoto M, Kaburaki T, Numaga J, Fujino Y, Kawashima H: Longterm infliximab treatment for Behçet's disease. Jpn J Ophthalmol 2007; 51: 239-240.
12. Niccoli L, Nannini C, Benucci M, Chindamo D, Cassarà E, Salvarani C, Cimino L, Gini G, Lenzetti I, Cantini F: Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: a 24-month follow-up study. Rheumatology (Oxford) 2007; 46: 1161-1164.
13. Benitez-del-Castillo JM, Martinez-de-la-Casa JM, Pato-Cour E, Méndez- Fernández R, López-Abad C, Matilla M, Garcia-Sanchez J: Longterm treatment of refractory posterior uveitis with anti-TNFalpha (infliximab). Eye 2005; 19: 841-845.
14. Sayarlioglu M, Cinal A, Topcu N, Demirok A: Effect of infliximab on refractory uveitis in Behçet's disease. Ann Pharmacother 2004; 38: 901-902.
15. Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, Markomichelakis N: Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med 2004; 140: 404-406.
16. Lanthier N, Parc C, Scavennec R, Dhôte R, Brézin AP, Guillevi L: Infliximab in the treatment of posterior uveitis in Behçet's disease: longterm follow-up in four patients. Presse Méd 2005; 34: 916-918.
17. Tognon S, Graziani G, Marcolongo R: Anti-TNF-alpha therapy in seven patients with Behçet's uveitis: advantages and controversial aspects. Ann NY Acad Sci 2007; 1110: 474-484.
18. Olivieri I, Latanza L, Siringo S, Peruz G, Di Iorio V: Successful treatment of severe Behçet's disease with infliximab in an Italian Olympic athlete. J Rheumatol 2008; 35: 930-932.
19. Olivieri I, Padula A, Leccese P, D'Angelo S, Giasi V: Long-lasting remission of severe Behçet's disease after the end of infliximab therapy. J Rheumatol 2009; 36: 855.
20. Al-Rayes H, Al-Swailem R, Al-Balawi M, Al-Dohayan N, Al-Zaidi S, Tariq M: Safety and efficacy of infliximab therapy in active Behçet's uveitis: an open-label trial. Rheumatol Int 2008; 29: 53-57.
21. Lee JH, Kim TN, Choi ST, Jang BI, Shin KC, Lee SB, Shim YR: Remission of intestinal Behçet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (infliximab). Korean J Intern Med 2007; 22: 24-27.
22. Naganuma M, Sakuraba A, Hisamatsu T, Ochiai H, Hasegawa H, Ogata H, Iwao Y, Hibi T: Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease. Inflamm Bowel Dis 2008; 14: 1259-1264.
23. Ju JH, Kwok SK, Seo SH, Yoon CH, Kim HY, Park SH: Successful treatment of life-threatening intestinal ulcer in Behçet's disease with infliximab: rapid healing of Behçet's ulcer with infliximab. Clin Rheumatol 2007; 26: 1383-1385.
24. Ribi C, Sztajzel R, Delavelle J, Chizzolini C: Efficacy of TNF α blockade in cyclophoshamide resistant neuro-Behçet disease. J Neurol Neurosurg Psychiatry 2005; 76: 1733-1735.
25. Kikuchi H, Aramaki K, Hirohata S: Effect of infliximab in progressive neuro-Behçet's syndrome. J Neurol Sci 2008; 272: 99-105.
26. Fujikawa K, Aratake K, Kawakami A, Aramaki T, Iwanaga N, Izumi Y, Arima K, Kamachi M, Tamai M, Huang M, Nakamura H, Nishiura Y, Origuchi T, Ida H, Eguchi K: Successful treatment of refractory neuro- Behçet's disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile. Ann Rheum Dis 2007; 66: 136-137.
27. Sarwar H, McGrath H Jr, Espinoza LR: Successful treatment of longstanding neuro-Behçet's disease with infliximab. J Rheumatol 2005; 32: 181-183.
28. Licata G, Pinto A, Tuttolomondo A, Banco A, Ciccia F, Ferrante A, Triolo G: Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behçet's syndrome. Ann Rheum Dis 2003; 62: 280-281.
29. Pipitone N, Olivieri I, Padula A, D'Angelo S, Nigro A, Zuccoli G, Boiardi L, Salvarani C: Infliximab for the treatment of neuro-Behçet's disease: a case series and review of the literature. Arthritis Rheum 2008; 59: 285-290.
30. Zouboulis CC, Turnbull JR, Martus P: Univariate and multivariate analyses comparing demographic, genetic, clinical, and serological risk factors for severe Adamantiades-Behçet's disease. Adv Exp Med Biol 2003; 528: 123-126.
31. Lee KH, Chung HS, Kim HS, Oh SH, Ha MK, Baik JH, Lee S, Bang D: Human alpha-enolase from endothelial cells as a target antigen of antiendothelial cell antibody in Behçet's disease. Arthritis Rheum 2003; 48: 2025-2035.
32. Zouboulis CC, Turnbull JR, Mühlradt PF: High seroprevalence of anti- Mycoplasma fermentans antibodies in patients with malignant aphthosis. J Invest Dermatol 2003; 121: 211-212.
33. Feigenbaum A: Description of Behçet's syndrome in the Hippocratic third book of endemic diseases. Br J Ophthalmol 1956; 40: 355-357.
34. Adamantiades B: Sur un cas d'iritis à hypopyon récidivant. Ann Oculist (Paris) 1931; 168: 271-278.
35. Behçet H: Über rezidivierende, aphthöse, durch ein Virus verursachte Geschwüre am Mund, am Auge und an den Genitalien. Dermatol Wochenschr 1937; 105: 1152-1157.
36. James DG: 'Silk route disease' (Behçet's disease). West J Med 1988; 148: 433-437.
37. Ohno S, Ohguchi M, Hirose S, Matsuda H, Wakisaka A, Aizawa M: Close association of HLA-Bw51 with Behçet's disease. Arch Ophthalmol 1982; 100: 1455-1458.
38. Papoutsis NG, Abdel-Naser MB, Altenburg A, Orawa H, Kötter I, Krause L, Pleyer U, Djawari D, Stadler R, Wollina U, Kohl PK, Gollnick HP, Kirch W, Ochsendorf FR, Keitel W, Martus P, Zouboulis CC: Prevalence of Adamantiades-Behçet's disease in Germany and the municipality of Berlin: results of a nationwide survey. Clin Exp Rheumatol 2006; 24(suppl 42):S125 (erratum published in Clin Exp Rheumatol 2007; 25: 507-508).
39. Adişen E, Oztaş M, Gürer MA: Treatment of idiopathic pyoderma gangrenosum with infliximab: induction dosing regimen or on-demand therapy? Dermatology 2008; 216: 163-165.
40. Juillerat P, Christen-Zäch S, Troillet FX, Gallot-Lavallée S, Pannizzon RG, Michetti P: Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Dermatology 2007; 215: 245-251.
41. Arishiro K, Nariyama J, Hoshiga M, Nakagawa A, Okabe T, Nakakoji T, Negoro N, Ishihara T, Hanafusa T: Vascular Behçet's disease with coronary artery aneurysm. Intern Med 2006; 45: 903-907.
42. Al-Otaibi LM, Porter SR, Poate TW: Behçet's disease: a review. J Dent Res 2005; 84: 209-222.
43. Zouboulis CC, Kötter I, Djawari D, Kirch W, Kohl PK, Ochsendorf FR, Keitel W, Stadler R, Wollina U, Proksch E, Söhnchen R, Weber H, Gollnick HP, Hölzle E, Fritz K, Licht T, Orfanos CE: Epidemiological features of Adamantiades-Behçet's disease in Germany and in Europe. Yonsei Med J 1997; 38: 411-422.
44. Hoxha FT, Hashani S, Krasniqi A, Pllana M, Komoni D, Pustina B, Sopa R, Zouboulis CC: Intestinal vasculitis in Adamantiades-Behçet disease presenting as acute abdomen. J Eur Acad Dermatol Venereol 2009; 23:1461-1463.
45. Aykutlu E, Baykal B, Akman-Demir G, Topcular B, Ertas M: Headache in Behçet's disease. Cephalalgia 2006; 26: 180-186.